NCT00634634 - Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 11, 2008

Primary Completion Date

April 20, 2019

Study Completion Date

April 28, 2023

Conditions

Metastatic Breast Cancer

Interventions

DRUG

Sorafenib

sorafenib dose will be given at a daily dose to be determined based upon the phase of study that patient is enrolled The phase II dose of sorafenib will be determined from the phase I portion of the study.

DRUG

Letrozole

Patients will take letrozole orally at a daily dose of 2.5 mg/day on Days 1 through 28

Trial Locations (4)

20007

Georgetown University Hospital, Washington D.C.

30322

Emory University, Atlanta

08901

Rutgers Cancer Institute of New Jersey, New Brunswick

08690

Cooper Hospital/University Medical Center, Voorhees Township